MDV: Multidose vial; NA: Not available ... Practices related to predrawing the vaccine into unmarked plastic syringes were observed that could impact patient safety and reduce vaccine potency.

The FDA will review a new prefilled syringe presentation of Shingrix (zoster vaccine recombinant, adjuvanted).

The French biotech is the first company to bring a chikungunya vaccine to market, getting FDA approval for its Ixchiq (VLA1553) shot in November 2023 and in Europe and Canada in June, for adults ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Valneva’s single-dose chikungunya vaccine for use in adults. Ixchiq is now the first vaccine approved in the UK to prevent ...

(RTTNews) - Valneva SE (VALN) a specialty vaccine company, on Wednesday announced that it is advancing to a Phase 3 trial for IXCHIQ, its single-dose chikungunya vaccine, in children aged 1 to 11 ...

The vaccine, Ixchiq, is already approved in the US, Europe and Canada to prevent the mosquito-borne viral disease in individuals aged 18 years and older. Valneva said the updated results from the ...

Valneva (NASDAQ:VALN) ADRs traded higher in the premarket on Tuesday after the French biotech posted additional data for its FDA-approved chikungunya vaccine, Ixchiq, from a Phase 3 trial for ...

The vaccine is manufactured at Valneva’s leading vaccine production site in Livingston, Scotland. The approval is based on IXCHIQ ® ’s final pivotal Phase 3 data, published in The Lancet ...

We observed tasks in the vaccine preparation process, from the time of removal of the vial or the syringe package from the refrigerator until the time it was ready to be administered to a patient.